Program Schedule

Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis

Session: Poster Abstract Session: Fungal Infections
Saturday, October 11, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Background: Coccidioidal meningitis is a morbid condition with severe consequences including stroke or the development of hydrocephalus. Adjunctive corticosteroid therapy has been examined in the treatment of other CNS infections and has shown a survival benefit in the treatment of tuberculous meningitis. We sought to determine if any benefit was observed in those given corticosteroid therapy during treatment of coccidioidomycosis associated cerebrovascular accident (CVA).

Methods: As part of a multicenter retrospective study all patients with coccidioidal meningitis were identified and underwent chart review. Clinical variables including demographic data, patient symptoms and exam findings, serum coccidioidal CF antibody titers, CSF results, and the onset of a CVA attributed to their diagnosis of coccidioidomycosis were abstracted.  The use of corticosteroids as adjunctive therapy was included for dose, duration, and the presence of additional CVA symptoms after starting corticosteroids.  

Results: One-hundred five patients with coccidioidal meningitis were identified and all were included for analysis.  A CVA occurred in 18/105 (17%) patients. Fifteen patients received corticosteroids as adjunctive therapy, while three received only standard antifungal treatment.  Dexamethasone was the most commonly prescribed corticosteroid and the majority of patients received 10mg followed by 4mg four times daily (9/15). All three patients without adjunctive therapy experienced a second CVA, while only 1/15 (7%) receiving adjunctive treatment experienced a second CVA. This difference was highly significant (P=0.0049). There was no difference in time to discharge, AEs, or patient mortality at 90 days.   

Conclusion: Adjunctive corticosteroid therapy reduced the rate of recurrent CVA in patients with coccidioidal meningitis and was well tolerated with few adverse events.  Those with coccidioidomycosis associated CVA may benefit from a corticosteroid taper.

George Thompson1, Sharon Wang, DO2, Robert Bercovitch, MD3, Michael Bolaris, MD4, Dane Van Den Akker, MD4, Rodrigo Lopez, MD5, Arash Heidari, M.D.6, Antonio Catanzaro, MD3, Jose Cadena Zuluaga, MD7, Peter Chin-Hong, MD8, Brad Spellberg, MD, FIDSA9, Janis Blair, MD10 and Royce H. Johnson, M.D., F.A.C.P.6, (1)UC-Davis, Davis, CA, (2)University of California - Davis, Sacramento, CA, (3)University of California - San Diego, La Jolla, CA, (4)Harbor - UCLA Medical Center, Torrance, CA, (5)University of Texas Health Science Center - San Antonio, San Antonio, TX, (6)Infectious Diseases, Kern Medical Center/UCLA, Bakersfield, CA, (7)UTHSCSA, San Antonio, TX, (8)Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA, (9)Harbor-UCLA Medical Center, Torrance, CA, (10)Division of Infectious Diseases, Mayo Clinic Hospital, Phoenix, AZ


G. Thompson, None

S. Wang, None

R. Bercovitch, None

M. Bolaris, None

D. Van Den Akker, None

R. Lopez, None

A. Heidari, None

A. Catanzaro, None

J. Cadena Zuluaga, None

P. Chin-Hong, None

B. Spellberg, GlaxoSmithKline, Adenium, Spero Therapeutics, Anacor, Synthetic Biologics, Novartis: Consultant, Consulting fee

J. Blair, None

R. H. Johnson, Astellas Pharma US: Speaker's Bureau, Speaker honorarium
Forest Phamaceuticals: Speaker's Bureau, Speaker honorarium
Pfizer Inc: Investigator, Research support
Chevron: Grant Investigator, Grant recipient

See more of: Fungal Infections
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, All Rights Reserved.

Follow IDWeek